Overall rank by patents
#26,606
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 12 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: H02J (CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY).
The verdict
Iontra holds 10 US patents across 12 technology areas, rank #26,606 of 50,000 tracked assignees.
Iontra Inc has been granted 10 US utility patents between 2019 and 2025, placing Iontra Inc at rank #26,606 across all assignees tracked by PlainPatent. This portfolio spans 12 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.3 claims per patent with primary concentration in H02J (CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY). As a US Corporation, Iontra Inc is one of the more focused assignees in the PatentsView dataset. By volume, Iontra sits between Interpace Diagnostics Corporation (10 patents, rank #26,602) and Iron Mountain Incorporated (10 patents, rank #26,610) - the closest US assignees by grant volume. The composite Innovation Score of 38.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 9 grants, compared with 1 in the 2015–2019 window, a +800% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Iontra Inc's 18.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 12 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Iontra Inc against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Interpace Diagnostics Corporation
10 patents
Interventional Spine, Inc.
10 patents
Intrinsic Value, LLC
10 patents
Invectys
10 patents
Ipass Inc.
10 patents
Ipsen, Inc.
10 patents
Iradimed Corporation
10 patents
Iron Mountain Incorporated
10 patents
Iontra Inc
10 patents
What this shows Iontra holds 10 patents at rank #26,606, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Iontra's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
38 Top 41% higher than 59% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 10.0% |
| 2021 | 1 | 10.0% |
| 2022 | 1 | 10.0% |
| 2024 | 1 | 10.0% |
| 2025 | 6 | 60.0% |
Top 12 of 12 technology areas
Overall rank by patents
#26,606
Across all tracked assignees
38.2 out of 100
How to use this portfolio
Iontra's 10 grants land it in the top 41% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.